Related Experiment Videos
Mid-term results with 1,503 CarboMedics mechanical valve implants
M J Dalrymple-Hay1, R K Pearce, S Dawkins
1Wessex Cardiothoracic Centre, Southampton General Hospital, UK.
The Journal of Heart Valve Disease
|July 11, 2000
Summary
The CarboMedics bileaflet prosthetic heart valve shows a low rate of complications in mid-term follow-up. This study analyzed clinical outcomes of 1,503 valve implantations, demonstrating good survival and freedom from reoperation.
Area of Science:
- Cardiovascular Surgery
- Biomedical Engineering
- Prosthetic Heart Valves
Background:
- The CarboMedics bileaflet prosthetic heart valve was introduced in 1986.
- The authors began implanting this valve in March 1991.
Purpose of the Study:
- To analyze the clinical experience and outcomes of the CarboMedics bileaflet prosthetic heart valve.
- Evaluate mid-term results of valve implantation.
Main Methods:
- 1,503 CarboMedics valves implanted in 1,350 patients between March 1991 and October 1998.
- Follow-up was 99% complete, totaling 4,342 patient-years.
- Analysis included survival, valve-related complications, and reoperation rates.
Main Results:
- Hospital mortality was 4.3%. Preoperative NYHA class, emergency surgery, and bypass time were associated with increased operative death risk.
- One-year survival was 92.0%, five-year survival was 80.0%.
- Freedom from valve-related complications at one and five years was 89.5% and 76.3%, respectively. Rates for bleeding, thromboembolism, endocarditis, thrombosis, and dysfunction were reported.
Conclusions:
- Mid-term results indicate a low incidence of valve-related complications with the CarboMedics prosthetic heart valve.
- The valve demonstrates favorable survival and low reoperation rates in this patient cohort.